Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Clentiazem. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1S known ✓ | Q13698 | 12/20 | 0.79 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.71 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.71 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.71 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.71 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.71 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | HRH2 | P25021 | 1/20 | 0.71 |
| ▸ | SCN1A | P35498 | 1/20 | 0.71 |
| ▸ | SCN4A | P35499 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.71 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clentiazem SCHEMBL7266652 | 1.00 | CACNA1S (0.79) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL7267636 | 1.00 | CACNA1S (0.79) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL7266655 | 1.00 | CACNA1S (0.79) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL387182 | 1.00 | CACNA1S (0.79) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL33910 | 0.95 | CACNA1S (0.86) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL7432489 | 0.95 | CACNA1S (0.86) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL33909 | 0.95 | CACNA1S (0.86) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL6616493 | 0.95 | CACNA1S (0.86) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL10830381 | 0.94 | CACNA1S (0.85) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Clentiazem SCHEMBL10830375 | 0.94 | CACNA1S (0.85) | CACNA1SCYP3A4TSHRABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 757 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | claimed |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2012054438-A1 | ANTI-PCSK9 | SCHERING CORPORATION (US) | 2012-04-26 | — | — | WO | claimed |
| US-20110033465-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2011-02-10 | — | — | US | claimed |
| EP-2205639-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009055783-A2 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | SCHERING CORPORATION (US) | 2009-04-30 | — | — | WO | claimed |
| EP-1363668-B1 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORP (US) | 2007-08-15 | — | — | EP | claimed |
| EP-1385548-B1 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORP (US) | 2007-05-23 | — | — | EP | claimed |
| EP-1785144-A2 | Combinations of bile acids sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | Shering Corporation (US) | 2007-05-16 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1541175-A2 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | Schering Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | claimed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| EP-0501442-B1 | 8-chloro-benzothiazepine-compound for prophylaxis and treatment of sequelae of cerebral neurocyte necrosis | TANABE SEIYAKU CO (JP) | 1995-12-06 | — | — | EP | claimed |
| EP-0501442-A1 | 8-chloro-benzothiazepine-compound for prophylaxis and treatment of sequelae of cerebral neurocyte necrosis | TANABE SEIYAKU CO., LTD. (JP) | 1992-09-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033465-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | CACNA1S 4746/4885KCNH2 3840/4885CACNA1F 4679/4885 |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | CYP46A1, FABP2, SREBF1 | CACNA1S 4081/4885KCNH2 4237/4885CACNA1F 3019/4885 |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | CACNA1S 4746/4885KCNH2 3840/4885CACNA1F 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.